SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
DMRA

Damora Therapeutics, Inc. (NASDAQ:DMRA)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$23.22-$1.08 (-4.44%)
 
Market cap
$1.44B
Insider Score
Health Score
Analyst consensus
Listed since
Oct 29, 2020
Market Cap$1.44B+38.5%
Revenue (ttm)$0
Net Income-$291.68M-1741.0%
EPS-$4.71-915.0%
Shares Out61.90M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume643,377
Open$23.81
Previous Close$24.30
Day's Range$23.09 - $24.51
52-Week Range$15.76 - $38.33
Beta1.51
AnalystsBuy
Price Target$52.50(+126.10%)
Earnings DateMar 18, 2027

About DMRA

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Address
Building 23, Waltham, MA, 02453, US
Market Cap
1.44 billion
Employees
7
Industrial Classification
Biotechnology

Damora Therapeutics, Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
3rd Percentile Overall Score
DMRA InsiderScore:32 / 99

Damora Therapeutics, Inc. scored higher than 3% of companies evaluated by InsiderBuying, and ranked 90th out of 102 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Damora Therapeutics, Inc. bought $252.9K of stock across 1 purchase in the last 90 days, the largest of them $252.9K.

Stake Increase

The average purchase added about 3% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$30.65K
Bought
$252.88K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $46.67 (+103.1%)

2 firms rating DMRA in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From DMRA’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-4.44%
5 Days
+6.12%
1 Month
+7.85%
6 Months
-6.60%
1 Year
+38.46%

$DMRA stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in DMRA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by DMRA's directors and management

Net Shares Purchased by Insiders−20k−10k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

DMRA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New DMRA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to DMRA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in DMRA

IWMiShares Russell 2000 ETF$29.92M
XBIState Street SPDR S&P Biotech ETF$18.03M
VXFVanguard Extended Market ETF$12.07M
IWOiShares Russell 2000 Growth ETF$7.47M
SCHASchwab U.S. Small-Cap ETF$6.25M
VTWOVanguard Russell 2000 ETF$5.97M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from DMRA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0.56
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
55

News check: Mix of corporate updates and routine announcements; trial launch question suggests uncertainty, offset by standard financial reporting.

Recent Insider Activity

Buys
1
Sells
4
Buy Value
$252.88K
Distinct Buyers
1

Insider Score Trend Over Time

-20.5 since Sep 28
0255075100Sep 28 — Insider Score 48.9Sep 29 — Insider Score 48.3Sep 30 — Insider Score 48.1Oct 1 — Insider Score 47.4Oct 2 — Insider Score 44.0Oct 3 — Insider Score 47.3Oct 4 — Insider Score 46.5Oct 5 — Insider Score 47.4Oct 6 — Insider Score 46.5Oct 7 — Insider Score 46.2Oct 8 — Insider Score 46.0Oct 9 — Insider Score 45.6Oct 10 — Insider Score 45.3Oct 11 — Insider Score 46.2Oct 12 — Insider Score 46.3Oct 13 — Insider Score 45.9Oct 14 — Insider Score 45.5Oct 15 — Insider Score 45.3Oct 16 — Insider Score 45.0Oct 17 — Insider Score 44.9Oct 18 — Insider Score 45.3Oct 19 — Insider Score 45.0Oct 20 — Insider Score 45.1Oct 21 — Insider Score 44.9Oct 22 — Insider Score 44.9Oct 23 — Insider Score 44.8Oct 24 — Insider Score 44.7Oct 25 — Insider Score 44.4Oct 26 — Insider Score 44.4Oct 27 — Insider Score 44.6Oct 28 — Insider Score 44.3Oct 29 — Insider Score 43.8Oct 30 — Insider Score 42.5Oct 31 — Insider Score 42.1Nov 1 — Insider Score 42.3Nov 2 — Insider Score 42.4Nov 3 — Insider Score 41.5Nov 4 — Insider Score 41.0Nov 5 — Insider Score 40.1Nov 6 — Insider Score 39.2Nov 7 — Insider Score 38.6Nov 8 — Insider Score 39.4Nov 9 — Insider Score 39.8Nov 10 — Insider Score 37.7Nov 11 — Insider Score 36.7Nov 12 — Insider Score 37.1Nov 13 — Insider Score 35.7Nov 14 — Insider Score 34.7Nov 15 — Insider Score 35.2Nov 16 — Insider Score 34.8Nov 17 — Insider Score 32.9Nov 18 — Insider Score 31.7Nov 19 — Insider Score 30.6Nov 20 — Insider Score 29.0Nov 21 — Insider Score 28.4Sep 28Oct 25Nov 21

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BBCVirtus Biotech Clinical Trials ETF0.83%
WCEOHypatia Women CEO ETF0.19%
XBIState Street SPDR S&P Biotech ETF0.16%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF0.15%
OPTZOptimize Strategy Index ETF0.14%
PJSMPGIM Jennison Small-Mid Cap Core Equity ETF0.12%
FFSMFidelity Fundamental Small-Mid Cap ETF0.06%
FSMOFidelity Fundamental Small-Mid Cap ETF0.06%
VFMOVanguard U.S. Momentum Factor ETF0.05%
IWOiShares Russell 2000 Growth ETF0.05%
VTWGVanguard Russell 2000 Growth ETF0.05%
PWSPacer WealthShield ETF0.03%

Weight is the stock’s share of each fund’s holdings.